Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Thousands of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
In functional products, Beauty Care posted higher revenue but lower profit due to increased overseas sales of functional oils and lower domestic sales of bioactive substances; Healthcare posted lower revenue and profit due to the reactionary decline in spot contract manufacturing projects for pharmaceutical intermediates from the previous interim period and lower overseas sales of phospholipids for pharmaceutical use; and Fine Chemicals posted higher revenue but lower profit because the pass-through of higher raw material costs into selling prices was deferred to the second half, despite higher sales of wool grease derivatives for industrial use. Environmental and hygiene products posted higher revenue and profit due to selling price revisions and expanded sales in the food business and medical and nursing care sectors. Interim net income attributable to owners of the parent increased due to the recognition of gains on sales of investment securities.
Not applicable
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Net Sales | ¥17,719 million (YoY +1.3%) |
| Operating profit | ¥2,648 million (YoY -11.1%) |
| Ordinary income | ¥2,852 million (YoY -8.0%) |
| Profit attributable to owners of the parent | ¥2,676 million (YoY +6.7%) |
| Net income per share | ¥123.40 |
| Equity ratio | End of the current fiscal period 81.8 / End of previous period 78.5 |
| Total assets | ¥63,699 million |
| Net assets | ¥53,146 million |
| Cash flows from operating activities | 931,781 Thousands of yen |
| Cash flows from investing activities | -4,466,223 Thousands of yen |
| Cash flows from financing activities | -1,131,340 Thousands of yen |
| Cash and cash equivalents at end of period | 8,682,527 Thousands of yen |
| Full-year earnings forecast | Net Sales ¥37,400 million (YoY +10.7%) / Operating profit ¥5,700 million (YoY +6.7%) / Ordinary income ¥6,000 million (YoY +7.7%) / Profit attributable to owners of the parent ¥5,200 million (YoY +17.4%) |
| Revision to Earnings Forecast | Net Sales No revision / Operating profit No revision / Ordinary income No revision / Profit attributable to owners of the parent No revision |
| Annual Dividend Forecast | 98 Yen → 104 Yen（+6.1%） |
| Segment revenue | Functional Products 13,875,855 Thousands of yen (YoY +0.1%), Environmental and Sanitation Products 3,719,415 Thousands of yen (YoY +5.6%), Other 124,501 Thousands of yen (YoY +6.5%) |
| Segment profit | Functional Products 2,302,246 Thousands of yen (YoY -14.4%), Environmental and Sanitation Products 310,892 Thousands of yen (YoY +19.1%), Other 35,621 Thousands of yen (YoY +16.7%) |
| Depreciation and amortization | 708,594 Thousands of yen |
| Impairment loss | 7,913 Thousands of yen |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets 400 Thousands of yen, Gain on sale of investment securities 1,165,283 Thousands of yen / Extraordinary loss Loss on disposal of fixed assets 51,775 Thousands of yen, Impairment loss 7,913 Thousands of yen, Provision for environmental measures 50,309 Thousands of yen |
| Disclosure regarding the going concern assumption | Not applicable |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | Not applicable |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person For institutional investors and analysts |
| Issued Shares at Period-End | 23,822,447 |
| Treasury Shares at Period-End | 2,129,390 |
| Factors Behind Changes in Business Performance | In functional products, Beauty Care posted higher revenue but lower profit due to increased overseas sales of functional oils and lower domestic sales of bioactive substances; Healthcare posted lower revenue and profit due to the reactionary decline in spot contract manufacturing projects for pharmaceutical intermediates from the previous interim period and lower overseas sales of phospholipids for pharmaceutical use; and Fine Chemicals posted higher revenue but lower profit because the pass-through of higher raw material costs into selling prices was deferred to the second half, despite higher sales of wool grease derivatives for industrial use. Environmental and hygiene products posted higher revenue and profit due to selling price revisions and expanded sales in the food business and medical and nursing care sectors. Interim net income attributable to owners of the parent increased due to the recognition of gains on sales of investment securities. |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In functional products, profit was weighed down by the reactionary decline in spot contract manufacturing projects for pharmaceutical intermediates, lower overseas sales of phospholipids for pharmaceutical use, and the deferral to the second half of the pass-through of higher raw material costs into selling prices. In contrast, environmental and hygiene products contributed to higher revenue and profit through selling price revisions and expanded sales in the food business and medical and nursing care sectors. Interim net income attributable to owners of the parent increased due to the recognition of gains on sales of investment securities.